

# Adalimumab: Amgevita the principal brand



July 2022

Between **1 March 2022** and **1 October 2022**, you will likely need to change from the Humira brand of adalimumab to Amgevita.

Amgevita is a citrate-free biosimilar adalimumab. Since 1 March 2022, it is the main funded brand in Aotearoa New Zealand.

You should continue to use Humira until you have talked to the person who prescribes your medicine to discuss a plan for your move to Amgevita.

Check that your prescription states which brand you should receive (Humira or Amgevita). This is to avoid inappropriate switching between brands.

## More information

[pharmac.govt.nz/adalimumab](https://pharmac.govt.nz/adalimumab)

[amgevita.co.nz](https://amgevita.co.nz)